Literature DB >> 12498807

A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.

Anna K Thomas1, Marcela V Maus, Waleed S Shalaby, Carl H June, James L Riley.   

Abstract

We compared the ability of two genetically modified myeloid cells, K562 and U937, to serve as artificial antigen-presenting cells (aAPC). Both aAPC were stably transfected with the low-affinity Fcgamma receptor CD32 (K32/U32 cells). K32 cells loaded with anti-CD3 and anti-CD28 Ab (K32/CD3/28) induced more rapid CD4 T-cell expansion than CD3/28-coated beads. In contrast, U32/CD3/28 induced high levels of CD4 T-cell thymidine uptake but were unable to sustain long-term T-cell expansion. K32 cells, but not U32 cells, loaded with anti-CD3 alone also stimulated CD4 T-cell growth and IL-2 secretion, indicating the expression of additional costimulatory molecules on K32 cells. We found constitutive expression of B7-H3 and a strong upregulation of mRNA encoding for IL-15, PD-L1, and PD-L2 after coculture with CD4 T cells activated by K32/CD3/28 but not U32/CD3/28. We conclude that K32 aAPCs are a robust system for clinical scale ex vivo expansion of CD4 T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498807     DOI: 10.1006/clim.2002.5277

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  31 in total

1.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

Review 2.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

3.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

Review 4.  PD-1 signaling in primary T cells.

Authors:  James L Riley
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

6.  Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies.

Authors:  Britta Eiz-Vesper; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-10       Impact factor: 3.747

7.  Transient stimulation expands superior antitumor T cells for adoptive therapy.

Authors:  Yuki Kagoya; Munehide Nakatsugawa; Toshiki Ochi; Yuchen Cen; Tingxi Guo; Mark Anczurowski; Kayoko Saso; Marcus O Butler; Naoto Hirano
Journal:  JCI Insight       Date:  2017-01-26

8.  Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.

Authors:  Kevin M Friedman; Laura E Devillier; Steven A Feldman; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2011 Nov-Dec       Impact factor: 4.456

9.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Authors:  Megan M Suhoski; Tatiana N Golovina; Nicole A Aqui; Victoria C Tai; Angel Varela-Rohena; Michael C Milone; Richard G Carroll; James L Riley; Carl H June
Journal:  Mol Ther       Date:  2007-03-20       Impact factor: 11.454

10.  Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.

Authors:  Colby R Maldini; Andrea C Love; Kevin W Tosh; Leo Li-Ying Chan; Kevin Gayout; Tim Smith; James L Riley
Journal:  J Immunol Methods       Date:  2020-08-01       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.